Skip to Content

Checkmate Pharmaceuticals, Inc.

Merger

  • Date:
  • 4/19/2022
  • Company Name:
  • Checkmate Pharmaceuticals, Inc.
  • Stock Symbol:
  • CMPI
  • Company Name - Buyer:
  • Regeneron Pharmaceuticals, Inc.
  • Stock Symbol - Buyer:
  • REGN
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 4/19/2022

Case Finder

Locate any case using the tools below.

NEW YORK, April 19, 2022 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).

On April 19, 2022, Checkmate announced that it had entered into an agreement to be acquired by Regeneron in a deal valued at approximately $250 million.  Pursuant to the merger agreement, Checkmate stockholders will receive $10.50 in cash for each share of Checkmate common stock owned.  The deal is scheduled to close in mid-2022.

Bragar Eagel & Squire is concerned that Checkmate’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Checkmate’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Checkmate Pharmaceuticals. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: